India : Efficacy of Covaxin is only 50% against symptomatic covid19

India : Efficacy of Covaxin is only 50% against symptomatic covid19

India : Efficacy of Covaxin is only 50% against symptomatic covid19

Two doses of Covaxin are 50% effective against symptomatic Covid19, according to the first real-world assessment of India’s indigenous coronavirus vaccine published in The Lancet Infectious Diseases journal.

Researchers also noted that the Delta variant was the dominant strain in India during the period of the study. At that time, the Delta variant approximately accounted for 80 % of all confirmed Covid19 cases.

Covaxin is an inactivated whole virus vaccine. According to international vaccine equity partnership Gavi, the science on which Covaxin is based represents “the well-established, and time-tested platform in the world of vaccine technology”. Inactivated whole virus vaccines carry the target pathogen, or some part of it, but with the genetic material destroyed.

This means that the virus introduced through the vaccine cannot actually replicate inside the body, although it is good enough to prompt the immune system into building a defence against it.

So far more than 130 million doses of Covaxin have been administered in India. Bharat Biotech and the government, which has widely promoted the shot, have sought to close the door on controversies involving the vaccine’s early authorization in January before it had completed phase 3 human trials, prompting widespread hesitancy in the country at the time.